- Conditions
- Heavy Menstrual Bleeding
- Interventions
- Sparrow Link, Sparrow Link (Sham)
- Device
- Lead sponsor
- Spark Biomedical, Inc.
- Industry
- Eligibility
- 14 Years to 45 Years · Female only
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 61
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Heavy Menstrual Bleeding, Uterine Fibroids
- Interventions
- Elagolix, Estradiol /norethindrone acetate (E2/NETA), E2/NETA Placebo, Elagolix Placebo
- Drug · Other
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 478 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 155
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 112 more
- Conditions
- Heavy Menstrual Bleeding
- Interventions
- Web-based data collection, Paper-based data collection
- Other
- Lead sponsor
- Women and Infants Hospital of Rhode Island
- Other
- Eligibility
- 18 Years to 51 Years · Female only
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Hemophilia, Menstrual Flow Excessive
- Interventions
- Recombinant FVIII Fc fusion product Eloctate, Recombinant FIX Fc fusion product Alprolix, Patient-operated diagnostic device for anemia AnemoCheck.
- Drug · Device
- Lead sponsor
- Emory University
- Other
- Eligibility
- 14 Years to 55 Years · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Menstruation; Heavy
- Interventions
- Nighttime Feminine Product
- Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Heavy Menstrual Bleeding
- Interventions
- Hysteroscopic myomectomy with Truclear, Medical therapy
- Procedure · Drug
- Lead sponsor
- All For Women Healthcare, Illinois
- Other
- Eligibility
- 21 Years to 80 Years · Female only
- Enrollment
- 69 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Uterine Fibroids
- Interventions
- Elagolix, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 51 Years · Female only
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Searcy, Arkansas • La Mesa, California + 35 more
- Conditions
- Menorrhagia, Heavy Menstrual Bleeding
- Interventions
- Tranexamic acid tablets (XP12B)
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 784 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 59
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 47 more
- Conditions
- Menorrhagia
- Interventions
- Extended treatment regimen using Her Option Cryotherapy
- Device
- Lead sponsor
- CooperSurgical Inc.
- Industry
- Eligibility
- 30 Years to 100 Years · Female only
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Wellington, Florida • Burlington, Massachusetts + 4 more
- Conditions
- Dysmenorrhea, Heavy Menstrual Bleeding, Contraception
- Interventions
- Transabdominal Ultrasound
- Diagnostic Test
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- 12 Years to 22 Years · Female only
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Heavy Menstrual Bleeding
- Interventions
- Volta System
- Device
- Lead sponsor
- Spark Biomedical, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Menorrhagia, Heavy Menstrual Bleeding
- Interventions
- Tranexamic acid tablets, Placebo tablets
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 83
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 76 more
- Conditions
- Uterine Fibroids, Endometriosis
- Interventions
- Relugolix Combination Tablet
- Drug
- Lead sponsor
- Sumitomo Pharma Switzerland GmbH
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 120
- States / cities
- Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 98 more
- Conditions
- Uterine Fibroids, Heavy Menstrual Bleeding
- Interventions
- Elagolix, Placebo for Estradiol/Norethindrone Acetate, Estradiol/Norethindrone Acetate, Placebo for Elagolix
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 51 Years · Female only
- Enrollment
- 378 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 103
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 89 more
- Conditions
- Menorrhagia
- Interventions
- Cerene(R) Cryotherapy Device
- Device
- Lead sponsor
- Channel Medsystems
- Industry
- Eligibility
- 25 Years to 50 Years · Female only
- Enrollment
- 242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 9
- States / cities
- Arlington Heights, Illinois • Naperville, Illinois • Fort Wayne, Indiana + 6 more
- Conditions
- Uterine Fibroids, Heavy Menstrual Bleeding
- Interventions
- Elagolix, Placebo for Estradiol/Norethindrone Acetate, Estradiol/Norethindrone Acetate, Placebo for Elagolix
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 51 Years · Female only
- Enrollment
- 413 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 92
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Costa Mesa, California + 79 more
- Conditions
- Adenomyosis
- Interventions
- Epelsiban, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 55 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 13
- States / cities
- Washington D.C., District of Columbia • West Palm Beach, Florida • Champaign, Illinois + 10 more
- Conditions
- Abnormal Uterine Bleeding, Unspecified, Uterine Bleeding Heavy
- Interventions
- EE 30mcg/LNG 150mcg, Placebo
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 14 Years and older · Female only
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 2
- States / cities
- Sacramento, California • St Louis, Missouri
- Conditions
- Uterine Fibroids, Heavy Menstrual Bleeding
- Interventions
- OBE2109, Placebo to match OBE2109, Placebo to match Add-back, Add-back
- Drug
- Lead sponsor
- ObsEva SA
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 511 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 23
- States / cities
- Chino, California • Huntington Park, California • San Diego, California + 19 more
- Conditions
- Menorrhagia
- Interventions
- Tranexamic acid
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 288 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 92
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 79 more
- Conditions
- Heavy Menstrual Bleeding
- Interventions
- Tranexamic Acid
- Drug
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 10 Years to 19 Years · Female only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 5
- States / cities
- Indianapolis, Indiana • Kansas City, Missouri • Akron, Ohio + 2 more
- Conditions
- Iron Deficiency Anemia, Heavy Menstrual Bleeding, Abnormal Uterine Bleeding
- Interventions
- Ferrous sulfate
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 9 Years to 22 Years · Female only
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Anemia, Iron Deficiency, Heavy Menstrual Bleeding
- Interventions
- Ferumoxytol, Ferrous Sulfate
- Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 76 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Adenomyosis, Heavy Uterine Bleeding, Dysmenorrhea
- Interventions
- Ulipristal Acetate
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 51 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee